IFP Advisors Inc Has $4.32 Million Holdings in Teva Pharmaceutical Industries Ltd. $TEVA

IFP Advisors Inc increased its position in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 19,910.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 138,271 shares of the company’s stock after acquiring an additional 137,580 shares during the period. IFP Advisors Inc’s holdings in Teva Pharmaceutical Industries were worth $4,315,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also made changes to their positions in the company. Allworth Financial LP boosted its position in shares of Teva Pharmaceutical Industries by 53.8% during the 4th quarter. Allworth Financial LP now owns 941 shares of the company’s stock worth $29,000 after acquiring an additional 329 shares in the last quarter. Grove Bank & Trust boosted its position in shares of Teva Pharmaceutical Industries by 300.0% during the 4th quarter. Grove Bank & Trust now owns 1,000 shares of the company’s stock worth $31,000 after acquiring an additional 750 shares in the last quarter. 1620 Investment Advisors Inc. boosted its position in shares of Teva Pharmaceutical Industries by 1,823.2% during the 4th quarter. 1620 Investment Advisors Inc. now owns 1,577 shares of the company’s stock worth $49,000 after acquiring an additional 1,495 shares in the last quarter. ANTIPODES PARTNERS Ltd acquired a new stake in shares of Teva Pharmaceutical Industries during the 4th quarter worth approximately $65,000. Finally, Rothschild Investment LLC boosted its position in shares of Teva Pharmaceutical Industries by 97.0% during the 3rd quarter. Rothschild Investment LLC now owns 2,738 shares of the company’s stock worth $55,000 after acquiring an additional 1,348 shares in the last quarter. Institutional investors and hedge funds own 54.05% of the company’s stock.

Insider Buying and Selling at Teva Pharmaceutical Industries

In related news, CEO Richard D. Francis sold 442,935 shares of Teva Pharmaceutical Industries stock in a transaction on Tuesday, March 3rd. The shares were sold at an average price of $32.36, for a total transaction of $14,333,376.60. Following the completion of the transaction, the chief executive officer owned 642,099 shares of the company’s stock, valued at $20,778,323.64. This trade represents a 40.82% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Christine Fox sold 21,258 shares of Teva Pharmaceutical Industries stock in a transaction on Thursday, April 30th. The stock was sold at an average price of $35.31, for a total transaction of $750,619.98. Following the transaction, the executive vice president directly owned 63,647 shares of the company’s stock, valued at $2,247,375.57. This represents a 25.04% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 1,280,269 shares of company stock valued at $42,755,980 over the last three months. 0.54% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several analysts recently issued reports on the stock. The Goldman Sachs Group increased their price target on shares of Teva Pharmaceutical Industries from $36.00 to $45.00 and gave the stock a “buy” rating in a research report on Monday, February 9th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a research report on Monday, April 20th. Bank of America increased their price target on shares of Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the stock a “buy” rating in a research report on Thursday, April 9th. Scotiabank increased their price target on shares of Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the stock a “sector outperform” rating in a research report on Thursday, January 29th. Finally, Truist Financial raised their target price on shares of Teva Pharmaceutical Industries from $42.00 to $45.00 and gave the company a “buy” rating in a research report on Thursday, April 30th. Nine equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $41.78.

Teva Pharmaceutical Industries Price Performance

TEVA stock opened at $34.32 on Thursday. The company has a fifty day moving average price of $31.70 and a 200-day moving average price of $30.80. The company has a market capitalization of $39.46 billion, a P/E ratio of 25.80, a PEG ratio of 3.29 and a beta of 0.86. Teva Pharmaceutical Industries Ltd. has a 52-week low of $14.99 and a 52-week high of $37.35. The company has a debt-to-equity ratio of 1.70, a quick ratio of 0.78 and a current ratio of 1.01.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings results on Tuesday, March 31st. The company reported $0.53 earnings per share (EPS) for the quarter. The firm had revenue of $3.98 billion during the quarter. Teva Pharmaceutical Industries had a net margin of 9.01% and a return on equity of 43.53%. As a group, equities analysts expect that Teva Pharmaceutical Industries Ltd. will post 2.49 EPS for the current year.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.